Pre-made Cixutumumab biosimilar ( Whole mAb, anti-IGF1R therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-108
Anti-IGF1R therapeutic antibody (Pre-made Cixutumumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Cixutumumab (IMC-A12) is a human monoclonal antibody for the treatment of solid tumors.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IGF1R therapeutic antibody (Pre-made Cixutumumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Eli Lilly;ImClone Systems;M. D. Anderson Cancer Center;National Cancer Institute (USA)|
|Conditions Discontinued||Breast cancer;Colorectal cancer;Head and neck cancer;Liver cancer;Neuroendocrine tumours;Non-small cell lung cancer;Oesophageal cancer;Pancreatic cancer;Prostate cancer;Rhabdomyosarcoma;Sarcoma;Soft tissue sarcoma;Solid tumours;Thymoma|
|Development Tech||Dyax Human Phage Display|